PARP inhibitors, used to treat tumors whose cells have problems repairing damaged DNA, become ineffective when cancer cells lose the DNA-modifying enzyme TET2.
August 2020. Full story at National Cancer Institute.
PARP inhibitors, used to treat tumors whose cells have problems repairing damaged DNA, become ineffective when cancer cells lose the DNA-modifying enzyme TET2.
August 2020. Full story at National Cancer Institute.